CHEBI:8212 - pimozide

Main ChEBI Ontology Automatic Xrefs Reactions Pathways Models
ChEBI Name pimozide
ChEBI ID CHEBI:8212
Definition A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one in which one of the nitrogens is substituted by a piperidin-4-yl group, which in turn is substituted on the nitrogen by a 4,4-bis(p-fluorophenyl)butyl group.
Stars This entity has been manually annotated by the ChEBI Team.
Supplier Information eMolecules:30555480, ZINC000000901155
Download Molfile XML SDF
more structures >>
Wikipedia License
Pimozide (sold under the brand name Orap) is a neuroleptic drug of the diphenylbutylpiperidine class. It was discovered at Janssen Pharmaceutica in 1963. It has a high potency compared to chlorpromazine (ratio 50-70:1). On a weight basis it is even more potent than haloperidol. It also has special indication for Tourette syndrome and resistant tics.
Read full article at Wikipedia
Formula C28H29F2N3O
Net Charge 0
Average Mass 461.54620
Monoisotopic Mass 461.22787
InChI InChI=1S/C28H29F2N3O/c29-22-11-7-20(8-12-22)25(21-9-13-23(30)14-10-21)4-3-17-32-18-15-24(16-19-32)33-27-6-2-1-5-26(27)31-28(33)34/h1-2,5-14,24-25H,3-4,15-19H2,(H,31,34)
InChIKey YVUQSNJEYSNKRX-UHFFFAOYSA-N
SMILES Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1
Roles Classification
Biological Role(s): H1-receptor antagonist
H1-receptor antagonists are the drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine.
serotonergic antagonist
Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists.
dopaminergic antagonist
A drug that binds to but does not activate dopamine receptors, thereby blocking the actions of dopamine or exogenous agonists.
Application(s): H1-receptor antagonist
H1-receptor antagonists are the drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine.
serotonergic antagonist
Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists.
antidyskinesia agent
Any compound which can be used to treat or alleviate the symptoms of dyskinesia.
dopaminergic antagonist
A drug that binds to but does not activate dopamine receptors, thereby blocking the actions of dopamine or exogenous agonists.
first generation antipsychotic
Antipsychotic drugs which can have different modes of action but which tend to be more likely than second generation antipsychotics to cause extrapyramidal motor control disabilities such as body rigidity or Parkinson's disease-type movements; such body movements can become permanent even after treatment has ceased.
View more via ChEBI Ontology
ChEBI Ontology
Outgoing pimozide (CHEBI:8212) has role antidyskinesia agent (CHEBI:66956)
pimozide (CHEBI:8212) has role dopaminergic antagonist (CHEBI:48561)
pimozide (CHEBI:8212) has role first generation antipsychotic (CHEBI:65190)
pimozide (CHEBI:8212) has role H1-receptor antagonist (CHEBI:37955)
pimozide (CHEBI:8212) has role serotonergic antagonist (CHEBI:48279)
pimozide (CHEBI:8212) is a benzimidazoles (CHEBI:22715)
pimozide (CHEBI:8212) is a heteroarylpiperidine (CHEBI:48585)
pimozide (CHEBI:8212) is a organofluorine compound (CHEBI:37143)
IUPAC Name
1-{1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one
INNs Sources
pimozida ChemIDplus
pimozide WHO MedNet
pimozide ChemIDplus
pimozidum ChemIDplus
Synonyms Sources
Pimozide KEGG COMPOUND
pimozide IUPHAR
Brand Names Sources
Halomonth DrugBank
Neoperidole DrugBank
Opiran DrugBank
Orap KEGG DRUG
Manual Xrefs Databases
2172 DrugCentral
C07566 KEGG COMPOUND
D00560 KEGG DRUG
DB01100 DrugBank
HMDB0015232 HMDB
LSM-2001 LINCS
Pimozide Wikipedia
View more database links
Registry Numbers Types Sources
2062-78-4 CAS Registry Number KEGG COMPOUND
2062-78-4 CAS Registry Number ChemIDplus
2062-78-4 CAS Registry Number NIST Chemistry WebBook
729089 Reaxys Registry Number Reaxys
Last Modified
22 February 2017